Summary
The immunogenic and antigenic properties of the cystic fibrosis glycopeptide and its normal counterpart were compared. BALBlc mice were immunized with either the cystic fibrosis glycopeptide or its normal counterpart and their spleen cells fused with X63NSl/I-Ag-4 (NSl) mouse myeloma cells. Four hybridization experiments (two with each glycopeptide) were performed in which different plating methods and screening assays were evaluated. Although an identical immunization procedure was used, 51 hybridoma cultures producing specific antibodies to the control glycopeptide and only 11 producing antibodies to the cystic fibrosis glycopeptide were obtained. Many of the monoclonal antibody preparations showed specificity toward the carbohydrate moiety of the glycopeptides and crossreacted immunologically with various glycoprotein preparations, whereas some were specific to the glycopeptides. The antibodies from the cloned hybridomas specific to the glycopeptide were used to compare serum fractions from controls and cystic fibrosis patients (10 samples in each group). Indistinguishable immunologic reactivity (antigenicity) between the controls and cystic fibrosis patients was demonstrated with the various monoclonal antibodies so far evaluated. toward this factor. Antiserum was produced in rabbits using partially purified factor, yet no specific antibodies toward the factor were detectable after adsorption with control serum (18) . Recently, using a similar methodology with guinea pigs, a specific antiserum to the CF-protein (22, 23) was obtained by Manson and Brock (13) . The antisera obtained postimmunization was adsorbed with sera from controls and was tested for specificity toward the CF-protein by rocket immunoelectrophoresis; The antiserum reaction seen was small but demonstrated a positive reaction with sera from 16 of 17 CF homozygotes, eight out of nine heterozygotes, and one of 15 normal controls (13) . Similar results were described by Wilson (20) after immunizing mice with the CFprotein.
In the present study, we used the hybridoma technique (9, 10) in an attempt to obtain specific monoclonal antibodies toward the purified glycopeptide with ciliary dyskinetic activity from CF patients and toward its normal counterpart (2) . The advantage of having a continuous, unlimited supply of monoclonal antibody with a defined specificity toward an antigenic determinant will avoid the methodologic problems encountered by antisera adsorption. By immunizing with both the CF glycopeptide and its normal counterpart, the immunogenic and antigenic properties of these preparations were compared.
MATERIALS AND METHODS

Speculation
Although these findings indicate that the cystic fibrosis glycopeptide and its normal counterpart differed markedly in their ciliary dyskinetic activity and in their immunogenicity, they revealed both structural and antigenic similarity.
Materials. Diethylaminoethyl (DEAE)-cellulose (Cellex-D) was obtained from Bio-Rad Laboratories (Richmond, CA). Hypoxanthine, thymidine, aminopterin, Tween 20, sepharose-4B, and Sephadex G-IOO were from Sigma Chemical Company (St. Louis, MO). Dulbecco's Modified Eagle's Medium (DMEM), fetal calf The presence of a cystic fibrosis (CF)-specific factor affecting serum, and Freund's complete adjuvant were from GIBCO the rhythmic beat of cilia from rabbit tracheal explants was first (Grand Island, NY). Rabbit antiserum to mouse immunoglobulin described in 1967 by Spock et at. (17) . These authors documented G (IgG), peroxidase conjugated (lot 14453), was from Cappel this biological activity (ciliary dyskinesia) in both CF sera and the Laboratories (Cochranville, PA) and rabbit antiserum to human euglobulin fraction of both patients and CF obligate heterozy-IgG was from Calbiochem-Behring Corporation (La Jolla, CA).
gotes. This phenomenon was not observed in sera and the euglob-Iodine-125 C 25 I] Radioiodination System Kit was purchased from ulin fraction from most controls. Recently (2) we purified a New England Nuclear Company (Rochester, NY). Polyethylene glycopeptide with a molecular weight of 4600 from sera of CF glycol was from Serva Chemical Company (Heidelberg, Germany) patients. This purified fraction caused marked mucociliary dyski-and pristane (2,6,10, 14-tetramethylpentadecane) was purchased netic activity on rabbit tracheal explants. Using the same meth-from Aldrich Chemical Company (Milwaukee, WI). BALBlc odology, a similar glycopeptide with a molecular weight of 5700 mice were from Jackson Laboratories (Bar Harbor, ME). The was purified from sera of controls. This "normal counterpart" did mouse myeloma cells, X63NSI/I-Ag-4 (NSI), and the purified not show any apparent biological activity on the rabbit tracheal goat antibodies to mouse IgG were kindly obtained from Dr. Z. explants, even in a 50-fold higher concentration. In both the CF Eshhar, Weizmann Institute. The following purified glycoprotein and control glycopeptides, the protein components revealed the preparations were obtained: fetuin, ovalbumin, and bovine subabsence of aromatic amino acids, and the carbohydrate component maxillary mucin from Sigma Chemical Company, ribonuclease-B was shown to be deficient in sialic acid (2) . and rabbit seromucoid from Worthington Biochemical CorporaAttempts to develop a quantitative, specific immunoassay to tion (Freehold, NJ), bovine transferrin from Miles Biochemicals detect Spock's ciliary dyskinetic factor in order to detect CF (Elkhart, IN), and lXI-acid glycoprotein from the American Red patients and heterozygotes have not been afforded much success. Cross. All other reagents were either reagent grade or the best In 1968, Tannenbaum (18) attempted to produce an antibody grade available.
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Serum and serum fractions. Blood specimens (I-IS ml) were obtained after signed, informed consent. Specimens were obtained from healthy volunteers with no family history of CF (age range from 14-30 years), from CF patients (from ages 2-26 years), and from obligate CF heterozygotes (ages 25-35 years). The clinical diagnosis of CF was confirmed by repeated sweat electrolyte analyses (sweat chloride: 70-105 meq/liter). All patients are followed and managed by the Louisiana CF Clinic. The blood was incubated for 30 min at 37°C, the clot separated and retracted for 3 h at 4°C. The serum was separated by centrifugation and stored at -20°C until use.
The IgG fractions from the serum samples were obtained by DEAE-cellulose column chromatography with 0.01 M potassium phosphate buffer, pH 8.0, followed by Sephadex G-IOO gel filtration in 0.05 M sodium phosphate buffer, pH 7.4. The purified glycopeptide preparations from controls and CF patients were obtained as previously described (2) . The samples were compared in a double-blind manner for ciliary dyskinetic activity on rabbit tracheal ex plants (2) . All glycopeptide preparations from CF patients revealed ciliary dyskinetic activity, whereas the preparations from controls showed no biological activity on the explants.
Insoluble immunosorbents. Human IgG fraction was covalently bound to cyanogen bromide activated sepharose-4B (IS). This immunoadsorbent was used to adsorb antibodies cross-reacting with human IgG from the purified goat antibodies to mouse IgG and from the peroxidase-conjugated rabbit antisera to mouse IgG. The same immunoadsorbent was used to purify rabbit antibodies to human IgG. Rabbit antisera to human IgG was adsorbed and the purified antibody eluted with 0.1 M acetic acid followed by exhaustive dialysis with phosphate buffered saline (0.14 M sodium chloride in 0.01 M phosphate buffer, pH 7.0; PBS) and concentration by negative pressure ultrafiltration.
Immunization of mice. One ml of the purified glycopeptide (from CF patients or controls), 0.5 mg/ml by Lowry (12) , was emulsified with one ml of Freund's complete adjuvant. BALB/c female mice were injected with 150,tt1 of the emulsion into their footpads. After 2 wk, the mice received a booster injection of the same emulsion, 100 ,ttl into the footpads and 150 ,ttl intramuscularly. Two wk later, blood specimens were obtained from the retro-orbital plexus, and circulating antibodies against the purified glycopeptides were measured using solid phase radioimmunoassay (RIA). Circulating antibodies were revealed in all the immunized mice, and the mice then received an intravenous booster of 100 ,ttl of the purified glycopeptide (0.5 mg/ml in PBS, pH 7.0). Three days later, the animals were sacrificed, spleens removed aseptically and used for hybridization.
Hybridoma production and plating techniques. Cell hybridization of the spleen cells from the immunized mice with the NS I myeloma cells, using polyethylene glycol, was performed as previously described (5, 6). Selection of the spleen lymphocyte-myeloma hybrids was performed using hypoxanthine-aminopterin-thymidine (HAT) in DMEM medium (DMEM containing 15% fetal calf serum supplemented with I-glutamine, sodium pyruvate, antibiotics, and fungizone). In the first set of fusions the cells were suspended to a final concentration of 2.5-4.1 X 10 4 viable cells per ml, and 2 ml aliquots were distributed in 24-well Costar plates (#3524; Costar, Cambridge, MA). In the second set of fusions, the cells were suspended to a final concentration of 1.4-2.0 X 10 5 cells per ml and were distributed in ISO ,ttl aliquots into 96-well microculture plates (#3596; Costar).
Cloning on semisolid agarose. Cloning of the hybridomas was performed on 0.3% soft agarose medium, as previously described (3) . The hybridoma cells were grown on the agarose-medium for approximately 7-10 days. Colonies of cells were picked using sterile pasteur pipettes and transferred to 96-well microculture plates. Subclones producing specific antibodies were then transferred into 2-ml DMEM culture media in the 24-well Costar plates, screened again for antibody production and transferred into IO-ml DMEM culture media in 100 X 20 mm sterile petri dishes. Monoclonal antibodies from these media were either used directly for experiments or were isolated by precipitation with ammonium sulfate at 45% saturation. Mouse IgG antibodies in these fractions were characterized by immunoelectrophoresis against goat antisera to mouse IgG, as previously described (2) .
Growing hybridomas in mice. The cultured hybridoma cells (2-3 X 10 7 ) were injected intraperitoneally into BALB/c mice that were primed 3-5 wk earlier with an intraperitoneal injection of 0.5 ml pristane. Ascites fluid containing 4-6 mg/ml monoclonal antibodies was obtained 2-3 wk later by abdominal puncture.
Screeningfor antibody production. Solidphase radioimmunoassay (RIA): A solid-phase RIA on polyvinyl chloride plates (Dynatech Laboratories, Inc.; Alexandria, VA) was used to assay for antibodies (19) . Plates were coated with the antigen by incubating with 100,tt1 antigen per well, 50 ,ttg/ml, at room temperature for I h. The plates were washed three times with PBS containing 0.5% bovine serum albumin (BSA) and 0.02% sodium azide (PBS/ BSA), and 100,tt1 of the hybridoma culture media was added and incubated for I h at room temperature. After this incubation, the plates were washed three times with PBS/BSA, and 100,tt1 of the second antibody, purified goat antibodies to mouse IgG, [12"1] labeled, were added. These purified goat antibodies to mouse IgG (human IgG adsorbed) were iodinated with [ 125 1] using the Radioiodination System Kit and diluted to a final concentration of 0.2 ,ttg/ml, 92.2 X 10 8 cpm/,ttg, in PBS/BSA. The plates were incubated for I h at room temperature with this second antibody, and after washing four times with PBS/BSA, the individual wells were cut and counted in a Beckman 8000 Gamma Counter. Both media from NS I myeloma cultures and PBS/BSA were used as blanks. The hybridoma cultures were first screened with the homologous IgG fraction, and once a cell culture was revealed to be positive, it was confirmed with the homologous glycopeptide. In order to determine the amount of antigen (purified glycopeptide or IgG fraction from controls or CF patients or purified rabbit antibodies to human IgG) bound to the solid phase, the wells were coated with 100,tt1 antigen, 50 ,ttg/ml, and after washing with PBS, [ 125 1]-labeled BSA was added. The extent of binding of the iodinated BSA to the antigen-coated wells was compared to that of wells coated with [ 125 1]-labeled BSA (arbitrarily defined as 100% binding). It was shown that the IgG preparations from controls and CF patients as well as purified rabbit antibodies to human IgG bound to 96-98% of the binding sites, whereas the purified glycopeptide preparations occupied only 30-40% of the binding sites. Using a higher concentration of the glycopeptides did not increase its binding.
Screening for antibody production. Enzyme-linked immunosorbent assay-ELISA (7): This assay was identical to the solid-phase RIA described above, but the plates were washed four times with PBS containing 0.05% Tween 20 (PBS/Tween 20), and as the second antibody, 100,tt1 of peroxidase-conjugated goat antibodies to mouse IgG (human IgG adsorbed, 1/1200 dilution) was used. After the last washing, 100 ,ttl of peroxidase substrate (0.006% hydrogen peroxide and 0.0 I% ortho-dianisidine in 0.1 M citratephosphate buffer, pH 5.0) were added. In the positive wells, yellow to brown color developed within 3-5 min. For some plates, screening was performed with both the solid-phase RIA and the solid-phase ELISA. Positive wells with the ELISA screen were those that had 300 cpm or above with the RIA.
RESULTS
Antibody titers in the immunized mice. Four preparations of the purified glycopeptide, two from controls and two from CF patients, were used for immunization. Groups of three mice each were immunized with the four antigens. Three days before hybridization, the immunized mice were bled and the serum (1/10 dilution in PBS) tested for the presence of antibodies toward the purified glycopeptides using solid-phase RIA. The results from one set of mice are shown in Table I . As shown in the Table, circulating antibodies of the IgG type were documented in all mice. Significantly higher titers were shown in the group of mice immunized with the control glycopeptide as compared to those in the second group. In the mice immunized with the glycopeptide from CF patients, the crossreactivity with the homologous antigen seemed better than with the heterologous antigen.
Hybridomas producing antibodies toward the glycopeptides. Spleen lymphocytes from the four different groups of mice were hybridized with the NS I myeloma cells. In the first set of fusion experiments (one group of mice immunized with the glycopeptide from a control and the second with the glycopeptide from a CF patient) the hybrid cells were plated in 24-well Costar plates; in the second set the cells were distributed in microtiter plates (see "Materials and Methods" for details). Screening for antibody production was begun 10 days after hybridization and repeated four times at 2-3 day intervals. The results are summarized in Table 2 . In both sets a significantly higher yield of antibodyproducing hybridomas was obtained with the control glycopeptide as compared to the glycopeptide purified from CF patients.
Wells containing antibody-producing hybridomas were transferred to 24-well Costar plates containing hypoxanthine and thymidine (RT, with no aminopterin) media and gradually into media without RT. These wells were shown to produce antibodies reacting with both the purified glycopeptide preparations and the IgG fractions. Each of these cultures was then screened with six IgG preparations: two from controls, two from CF patients, and two from obligate heterozygotes. Indistinguishable immunologic reactivity was demonstrated between each of the various antibodyproducing hybridomas tested and the different IgG preparations. The results of some of these experiments are shown in Table 3 .
Antigenic specificity of the monoclonal antibodies. Twelve antibody-producing hybridomas, eight obtained from the immunization with the control glycopeptide and four with the CF glycopeptide, were chosen for further studies. These were cloned on semisolid agarose, and antibody-producing clones were selected. The antibodies were separated from media using ammonium sulfate fractionation, and the subcloned hybridoma cells were injected intraperitoneally into pristane-sensitized mice. The monoclonal antibodies obtained were compared to mouse serum IgG fraction by immunoelectrophoresis. The results are shown in Figure 1 . Each of the various hybridomas matched a narrow section from the serum IgG immune precipitin arc. Within the IgG electrophoretic range, the hybridomas differed in their mobilities. The antigenic specificity of the cloned hybridoma antibody preparations toward the purified glycopeptides and IgG preparations (control and CF) and toward seven, commercially available, purified gly- Sample tested  C-I-92  C-X-12  C-XII-I  CF-II-3   Control sera  I  1178  1246  2026  2058  2  1227  1344  2107  2316  3  1186  1264  2260  1809  4  1205  1315  1994  2248  5  1170  1151  1977  2029  6  1200  1071  2037  2122  7  1153  1196  2060 coprotein preparations was determined using solid-phase RIA. From the 12 different antibody preparations examined, four revealed immunologic reactivity with the purified glycopeptides and IgG preparations but with none of the other glycoproteins, whereas eight showed immunologic reactivity with the purified glycopeptides, IgG fractions, as well as the glycoproteins tested.
MS
Comparison of IgG fractions from controls and CF patients using glycopeptide-specific monoclonal antibodies. The four monoclonal antibody preparations reacting immunologically with the control and CF glycopeptides and IgG fractions but not with any of the other glycoproteins examined were used in the following experiment. In order to compare a large number of IgG fractions from controls and CF patients, a four-component RIA was used, as follows: purified rabbit antibodies to human IgG were applied to the wells of the microtiter plates (100 iLl/well, 0.1 mg/ml) and incubated for 1 h at room temperature. After washing the plates with PBS/BSA, 200 iLl serum from controls or CF patients (1/20 dilution in PBS) was applied and incubated for 1 h at room temperature. By this method, a constant amount of the IgG fraction from the serum was bound in each well. The specific monoclonal antibody preparations were added, followed by [ l25 II-labeled second antibody as described in the RIA procedure. The results are shown in Table 4 . No statistically significant differences were observed between the immunologic reactivity of the control and CF fractions with the monoclonal antibody preparations compared.
DISCUSSION
Recently we have described the purification and characterization of a serum glycopeptide from controls and CF patients. Both revealed marked structural similarities but differed significantly in their biological activity toward rabbit tracheal explants. These glycopeptide preparations were dissociated from IgG fractions with 8 M urea and were purified by size fractionation and chromatography (2) . In the present study, a significantly lower titer of circulating antibodies was determined in mice immunized with the glycopeptide from CF patients as compared to those immunized with its normal counterpart ( Table 1) . The circulating antibodies in mice immunized with the glycopeptide from CF patients showed significantly higher reactivity with this antigen than with its normal counterpart. The antibodies from mice immunized with the control glycopeptide revealed similar reactivity with both the control and CF glycopeptides (Table 1) . The results in Table 1 seem to confirm a previous report (21) documenting circulating antibodies in mice immunized with ciliary dyskinetic substances. Encouraged by the evidence of circulating antibodies toward the glycopeptides and the differences in immunologic reactivity, hybridization experiments to obtain monoclonal antibodies were done.
Four hybridization experiments, two with each of the glycopeptide preparations, were performed. As shown in Table 2 , a much higher yield of antibody-producing hybridoma cultures was obtained using the control glycopeptide as an immunogen when compared to the glycopeptide from CF patients. In the two sets of experiments (Table 2 ) different plating techniques were used. The observation of a significantly higher yield with the control glycopeptide was documented with both techniques. For each set of experiments, a different shipment ofBALB/c mice (from Jackson Laboratories) was used. The mice were divided randomly into two groups, one immunized with the control glycopeptide and one with the glycopeptide from CF patients. An identical immunization procedure was used for all groups; thus, the possibility of individual variability seems highly unlikely. The observations summarized in Table 2 indicate that the control glycopeptide acts as a better immunogen when compared to the glycopeptide purified from CF patients.
Relatively low binding of the purified glycopeptides to the polystyrene microtiter plates used in the solid-phase RIA was observed. As these glycopeptides were dissociated from the IgG fraction of serum, this decreased binding of the purified glycopeptides was circumvented by using IgG as the antigen bound to the plastic. A technical problem we encountered using IgG as the antigen was its crossreactivity with purified goat antibodies to mouse IgG both in the solid-phase RIA and ELISA. This resulted in relatively high background that was fully corrected by adsorbing the second antibody with insolubilized human IgG. After such adsorption, the background was only 1-4% of the positive readings.
All the hybridomas obtained had similar immunologic reactivity with the IgG fractions from controls, CF patients, and obligate heterozygotes. Examples are shown in Table 3 . Twelve hybridomas, eight from the immunization with the control glycopeptide and four from the immunization with the CF glycopeptide, were chosen and further subcloned. The antibody fractions of the subcloned hybridomas reacted immunologically with the purified glycopeptides and the IgG fractions from both controls and CF patients. In order to determine if the specificity of these monoclonal antibodies was toward the polypeptide component of the glycopeptide or toward the oligosaccharide moiety, their immunologic reactivity with seven different purified glycoproteins was tested. These glycoproteins were chosen in order to represent oligosaccharides linked to the polypeptide via either an N-linkage or an O-linkage, as well as both "simple" and "complex" oligosaccharide chains (11). Eight of the 12 subcloned hybridoma antibody preparations reacted immunologically with all of the glycoproteins tested. This observation indicates that their specificity was directed against antigenic determinants of the oligosaccharides. Four of the 12 subcloned hybridomas revealed specificity only toward the glycopeptides and did not crossreact with any of the glycoproteins tested. This latter group of antibodies is most likely directed against antigenic determinants of the polypeptide component of the glycopeptide and not to the oligosaccharide portion. Indistinguishable immunologic reactivity was observed using these specific monoclonal antibody preparations with both CF and control purified glycopeptides and their IgG fractions. Very similar immunologic reactivity was shown when these monoclonal antibodies with restricted specificity were tested with a larger number of IgG fractions from control and CF patients (Table 4) .
Although antigenic identity was revealed between the CF glycopeptide and its normal counterpart (Tables 3 and 4) , marked differences were observed in their immunogenicity (Tables I and  2) . A possible explanation is that the altered immunogenicity reflects differences in the adjuvant effect of the oligosaccharide component of these preparations. Another explanation is that the dose of a polysaccharide immunogen required for antibody production versus that inducing immunologic tolerance in mice differs according to the size and structure of the carbohydrate component; thus, a different equilibrium between tolerance and immunogenicity was obtained with the two glycopeptide preparations. If the structural difference between the CF glycopeptide with the mucociliary activity and its normal counterpart is in their polysaccharide component, this might account for the differences in their immunogenicity. Different immunization protocols, where both IgM and IgG antibody production will be assessed, are necessary to reveal possible subtle antigenic differences. Another immunologic option to reveal such differences might be by inducing immunologic tolerance in newborn mice using either the CF or control glycopeptide and subsequently immunizing with the alternate glycopeptide.
The possibility of an abnormality in some aspect of glycoproteins as the underlying, inherited defect in CF has been suggested by many investigators (I, 4, 8, 14, 16) . We have previously suggested that the mucociliary activity observed in the glycopeptide purified from CF patients, absent in its "normal counterpart," might be a consequence of such a generalized phenomenon of abnormal synthesis or degradation in glycoproteins and glycopeptides (2) . The present observation that the monoclonal antibodies directed toward the polypeptide component of the glycopeptide revealed antigenic identity with both the control and CF glycopeptides further supports the possibility that the mucociliary activity is secondary to differences in the structure of the oligosaccharide components.
